Stock CVAC CUREVAC N.V.
Add to a list
To use this feature you must be a member
Log inSign up

CureVac N.V. Stock

Equities

CVAC

NL0015436031

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-06-05 pm EDT 		Pre-market 07:13:14 am
4.53 USD +12.69% Intraday chart for CureVac N.V. 5.06 +11.70%
May. 28 CureVac, GSK Begin Dosing in Phase 2 Study for Seasonal Influenza Vaccine Candidate MT
May. 28 CureVac N.V. Announces Dosing of First Participant in a Phase 2 Study in Seasonal Influenza; Development in Collaboration with GSK CI

Financials

Sales 2024 * 55.9M 60.84M Sales 2025 * 86.34M 93.98M Capitalization 934M 1.02B
Net income 2024 * -211M -230M Net income 2025 * -130M -142M EV / Sales 2024 * 14.6 x
Net cash position 2024 * 117M 127M Net cash position 2025 * 26.5M 28.85M EV / Sales 2025 * 10.5 x
P/E ratio 2024 *
-4.34 x
P/E ratio 2025 *
-7.77 x
Employees 1,086
Yield 2024 *
-
Yield 2025 *
-
Free-Float 54.73%
More Fundamentals * Assessed data

Chart CureVac N.V.

Dynamic Chart

Latest news about CureVac N.V.

CureVac, GSK Begin Dosing in Phase 2 Study for Seasonal Influenza Vaccine Candidate MT
CureVac N.V. Announces Dosing of First Participant in a Phase 2 Study in Seasonal Influenza; Development in Collaboration with GSK CI
CureVac N.V. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
CUREVAC : Significant cash drain in the Q1 Alphavalue
Health Care Up as Vaccine Makers Gain - Health Care Roundup DJ
CUREVAC : A missed opportunity Alphavalue
UBS Cuts CureVac Price Target to $14 From $18, Maintains Buy Rating MT
Leerink Partners Downgrades CureVac to Market Perform From Outperform, Sets Price Target at $4 MT
CureVac N.V. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
CureVac Begins Early Stage Portion of Investigational Vaccine Trial MT
CureVac Hires New Chief Business Officer MT
CureVac, GSK Launch Phase 1/2 Trial of Bird Flu Vaccine Candidate MT
Transcript : CureVac N.V., Q4 2023 Earnings Call, Apr 24, 2024
Earnings Flash (CVAC) CUREVAC Posts Q4 Revenue EUR22.6M MT
CureVac Appoints Thaminda Ramanayake as New Chief Business Officer, Effective June 1, 2024 CI
More news

Latest transcript on CureVac N.V.

Logo CureVac N.V.
CureVac N.V., Q4 2023 Earnings Call, Apr 24, 2024
More transcripts

Analyst Recommendations on CureVac N.V.

CUREVAC : Significant cash drain in the Q1 Alphavalue
CUREVAC : A missed opportunity Alphavalue
UBS Cuts CureVac Price Target to $14 From $18, Maintains Buy Rating MT
Leerink Partners Downgrades CureVac to Market Perform From Outperform, Sets Price Target at $4 MT
Kempen Upgrades CureVac to Buy From Neutral, Price Target is $10 MT
More recommendations

Press releases CureVac N.V.

CureVac Announces Dosing of First Participant in a Phase 2 Study in Seasonal Influenza, Development in Collaboration with GSK AQ
CureVac Announces Dosing of First Participant in a Phase 2 Study in Seasonal Influenza; Development in Collaboration with GSK EQ
CureVac N : Proxycard AGM 2024 PU
CureVac N : Dutch Statutory Board Report and Financial Statements of CureVac N.V. 2023 PU
CureVac N : Interim Condensed Consolidated Statements of Operations and Other Comprehensive Income (Loss) - Form 6-K PU
More press releases

News in other languages on CureVac N.V.

Öl- und Bankentitel schwach - EZB wirft Schatten voraus
XETRA-SCHLUSS/DAX schwächer - der Bund macht Kasse
CureVac gibt Impfung des ersten Teilnehmers in einer Phase-2-Studie zur saisonalen Grippe bekannt; Entwicklung in Zusammenarbeit mit GSK
CureVac gibt Impfung des ersten Teilnehmers in einer Phase-2-Studie zur saisonalen Grippe bekannt; Entwicklung in Zusammenarbeit mit GSK
Starke Einkaufsmanager verderben Nvidia-Laune
More news

Quotes and Performance

1 day+12.13%
1 week+19.53%
Current month+16.45%
1 month+44.73%
3 months+36.04%
6 months-16.42%
Current year+7.60%
More quotes

Highs and lows

1 week
3.73
Extreme 3.725
4.57
1 month
2.85
Extreme 2.8503
4.57
Current year
2.22
Extreme 2.215
4.57
1 year
2.22
Extreme 2.215
12.36
3 years
2.22
Extreme 2.215
125.66
5 years
2.22
Extreme 2.215
151.80
10 years
2.22
Extreme 2.215
151.80
More quotes

Managers and Directors - CureVac N.V.

Managers TitleAgeSince
Alexander Zehnder CEO
 Chief Executive Officer 54 23-03-27
Pierre Kemula DFI
 Director of Finance/CFO 50 16-10-31
Malte Greune COO
 Chief Operating Officer 59 21-06-30
Members of the board TitleAgeSince
Craig Tooman BRD
 Director/Board Member 58 19-05-31
Michael Brosnan BRD
 Director/Board Member 69 23-06-18
Klaus Schollmeier BRD
 Director/Board Member 67 22-06-21
More insiders

ETFs positioned on CureVac N.V.

Name Weight AuM 1st Jan change Investor Rating
ISHARES MSCI GERMANY SMALL-CAP ETF - USD ETF iShares MSCI Germany Small-Cap ETF - USD
0.74% 17 M€ -.--% -
BMO MSCI GENOMIC INNOVATION INDEX ETF - CAD ETF BMO MSCI Genomic Innovation Index ETF - CAD
0.06% 2 M€ -.--%
LEVERAGE SHARES 3X LONG BIOTECHNOLOGY ETP SECURITIES - USD ETF Leverage Shares 3x Long Biotechnology ETP Securities - USD
0.04% 0 M€ 0.00% -
More ETFs positioned on CureVac N.V.

Quotes

Date Price Change Volume
24-06-05 4.53 +12.13% 2,020,818
24-06-04 4.04 -6.91% 1,967,037
24-06-03 4.34 +11.57% 2,219,466
24-05-31 3.89 +3.18% 1,105,122
24-05-30 3.77 -0.53% 860,410

Delayed Quote Nasdaq, June 05, 2024 at 04:00 pm EDT

More quotes

Company Profile

CureVac AG is a clinical-stage biopharmaceutical company, The Company strives to create transformative medicines to protect and improve people’s lives. Fueled by proprietary RNA technology platform combined with two decades of science and manufacturing, The Company is dedicated to creating novel treatments that enable the body to make its own prophylactic and therapeutic drugs.
Sector
Biotechnology & Medical Research
Calendar
2024-06-11 - Goldman Sachs Global Healthcare Conference
More about the company

Income Statement Evolution

More financial data

Ratings for CureVac N.V.

Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
9
Last Close Price
4.169 EUR
Average target price
8.728 EUR
Spread / Average Target
+109.35%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
CUREVAC N.V. Stock CureVac N.V.
+7.60% 1.01B
MODERNA, INC. Stock Moderna, Inc.
+55.70% 59.34B
LONZA GROUP AG Stock Lonza Group AG
+41.08% 40.24B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-5.39% 39.88B
CELLTRION, INC. Stock Celltrion, Inc.
-5.56% 28.55B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+16.46% 27.26B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-20.56% 19.23B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+33.03% 12.61B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+25.85% 12.28B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+2.72% 12.49B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. CVAC Stock